Stockreport

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma [Yahoo! Financ...

Citius Oncology, Inc.  (CTOR) 
PDF LYMPHIR was well-tolerated with no dose-limiting toxicities observed CRANFORD, N.J. March 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: C [Read more]